Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Celldex TherapeuticsFRA:TCE2 +0.03%59 Cash Ratio is 11.70 as of Jun. 2026, which is 2% above its 10-year median of 11.51. GuruFocus rates FRA:TCE2 with a GF Score™ of 59/100 and a GF Value™ of €1.81 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,385 Biotechnology companies, Celldex Therapeutics ranks better than 83.75% on this metric.
Celldex Therapeutics has a Cash Ratio of 11.70. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Celldex Therapeutics's Cash Ratio or its related term are showing as below:
FRA:TCE2'
s Cash Ratio Range Over the Past 10 Years
Min: 4.91 Med: 11.51 Max: 31.34
Current: 11.7
During the past 13 years, Celldex Therapeutics's highest Cash Ratio was 31.34. The lowest was 4.91. And the median was 11.51.
FRA:TCE2's Cash Ratio is ranked better than 83.75% of 1385
companies
in the Biotechnology industry
Industry Median: 2.96
vs FRA:TCE2: 11.70
Celldex Therapeutics (FRA:TCE2) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Celldex Therapeutics Cash Ratio Related Terms
Celldex Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Celldex Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TCE2 vs IRON, QURE, ATAI: Cash Ratio Comparison
For the Biotechnology subindustry, Celldex Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celldex Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Celldex Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Celldex Therapeutics (FRA:TCE2) has a Cash Ratio of 11.70 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Celldex Therapeutics and its competitors. This is near median its historical median of 11.51. Over the past decade, Celldex Therapeutics' Cash Ratio has ranged from 4.91 to 31.34. According to the industry distribution chart, Celldex Therapeutics ranks #225 out of 1385 companies in the Biotechnology industry, placing it in the top 16.2%.
Is Celldex Therapeutics' Cash Ratio too high?
Celldex Therapeutics' current Cash Ratio of 11.70 is near median its 10-year median of 11.51. Over the past 10 years, this metric has ranged from a low of 4.91 to a high of 31.34. The Biotechnology industry median Cash Ratio is 2.96. Celldex Therapeutics' value of 11.70 is 295.3% above this industry median. Based on the distribution chart, Celldex Therapeutics ranks #225 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Celldex Therapeutics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Cash Ratio compare to IRON and QURE?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #225 out of 1385 companies for Cash Ratio. This places Celldex Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. Celldex Therapeutics' value of 11.70 is 295.3% above this benchmark. Historically, Celldex Therapeutics' own Cash Ratio has ranged from 4.91 to 31.34 over the past decade. While the company's 10-year median is 11.51 vs. the industry median of 2.96, Celldex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current Cash Ratio of 11.70 is 295.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Celldex Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current Cash Ratio is 11.70, which is near median its own 10-year median of 11.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (FRA:TCE2) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.81, compared to a current price of €35.63 — trading 1868.5% above its estimated fair value. The current Cash Ratio is 11.70, which is near median its 10-year median of 11.51 and 295.3% above the Biotechnology industry median of 2.96. Celldex Therapeutics' overall GF Score™ is 59/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Celldex Therapeutics (FRA:TCE2), the current Cash Ratio is 11.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celldex Therapeutics (FRA:TCE2) Overvalued in 2026?
Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued.
The current stock price of €35.63 is trading 1868.5% above its estimated GF Value™ of €1.81.
GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:TCE2:
Cash Ratio: 11.70 (near median its 10-year median of 11.51)
GF Value™: €1.81 vs. price of €35.63 (1868.5% above fair value)
Industry Position: 295.3% above the Biotechnology median (#225 of 1385)
No single metric tells the full story. See the FRA:TCE2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
59GF Score
Get the complete analysis for FRA:TCE2
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TCE2 has been successfully added to your 
